A Phase I/II Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukemia

Registry ID

EUCTR2009-017147-33

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

AGMT gemeinnützige GmbH

Start date

2010-02-10

Completion date

2016-02-08

Last update

2026-08-16

Conditions

• Chronic Myelomonocytic Leukemia (CMML)

Summary

Phase I: The primary objective of the phase I trial is to determine the MTD (maximum tolerated dose) of lenalidomide. Phase II: The primary objective of the phase II trial is to determine the hematologic response achieved with lenalidomide administered in subjects at the MTD determined in phase I.

Locations

• , , Austria

Related clinical trials

• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
• Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
• A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
• A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

View on source registry